The present disclosure relates to inhalable pharmaceuticals. Specifically, the present disclosure relates to a composition comprising inhalable microparticles comprising hydroxychloroquine, aspirin, a copolymer and at least one surfactant. Further, the present invention also relates to a process of preparing the same. The 10 composition of the present invention may be used for management of acute respiratory disease and cardiovascular complications associated with COVID and SARS.
SANDEEP ARORA, SUKHBIR SINGH, NEELAM SHARMA